Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

EU approves first gene therapy for children

The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe.

Read More »

U.S. sees first case of bacteria resistant to all antibiotics

U.S. health officials reported the first case in the country of a patient with an infection resistant to all known antibiotics, and expressed grave concern that the superbug could pose serious danger for routine infections if it spreads.

Read More »

Thermo Fisher Scientific Antes Up $4.2 Billion for FEI

Life sciences giant Thermo Fisher Scientific ponied up $4.2 billion to buy Oregon-based FEI Co., gaining access to that company’s electron microscopy technology.

Read More »

FDA Approves First Implantable Device for Opioid Dependency

Titan Pharmaceuticals announced that the U.S. FDA approved Probuphine (buprenorphine) implant for long-term maintenance of opioid dependence.

Read More »

Gilead, Biogen, Jazz Pharma Subpoenaed as Feds Investigate Drugmaker-Charity Connections

Biogen, Gilead Sciences, and Jazz Pharmaceuticals are the latest drug companies to disclose that they have received federal subpoenas related to their relationships with charitable nonprofits. Although there are few details, both Gilead and Jazz did say that the subpoenas were issued by the U.S. Attorney for the District of Massachusetts.

Read More »

Embattled Valeant Reportedly Spurned a Takeover Offer from Takeda and TPG

In what some may have seen as “turnaround is fair play,” embattled drugmaker Valeant Pharmaceuticals – known for its aggressive growth by mergers and acquisitions strategy – rejected a takeover bid from Takeda Pharmaceuticals and TPG Capital Management LP before the Joe Papa era began, Business Insider reported.

Read More »

Genentech’s Gazyva Meets Primary Endpoint Early in Late-Stage Study

Interim data from a late-stage trial shows Genentech’s Gazyva for the treatment of untreated follicular lymphoma showed a significant difference in the staving off death or reducing the risk of disease progression when compared to Rituxan.

Read More »

Starboard Delivers Letter to Depomed Shareholders

Starboard Value LP, one of the largest shareholders of Depomed Inc. with an ownership interest in approximately 9.9% of Depomed’s outstanding shares, announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees.

Read More »

Walgreens’ Execs Ignored Doubts in Theranos’ Technology in Fear of Deal Crumbling

Deerfield, Ill.-based Walgreens never vetted Theranos blood-testing technology before forming a partnership with the Palo-Alto, Calif. company, the Wall Street Journal reported.

Read More »

FORUM Pharma CEO Quits Amid Layoffs

FORUM Pharmaceuticals is laying off 77 people starting immediately, with another 12 job losses possible. There are unconfirmed rumors that the company may shut down.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom